

# **Product Introduction**

## LY2811376

LY2811376 is the first orally available non-peptidic  $\beta$ -secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM, that act to decrease A $\beta$  secretion with EC50 of 300 nM, demonstrated to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin. Phase 1.

Molecular Weight (MW):	320.36	
Formula:	$C_{15}H_{14}F_2N_4S$	
Solubility (25°C)	DMSO 16 mg/mL	
* <1 mg/ml means slightly	Water <1 mg/mL	NH2
soluble or insoluble:	Ethanol 64 mg/mL	
Purity:	>98%	
Storage:	3 years -20°C Powder	
	6 months-80℃in DMSO	
CAS No.:	1194044-20-6	

#### Technical Data:

### **Biological Activity**

LY2811376 demonstrates concentration-dependent inhibition of hBACE1 with an IC50 of 239 and 249 nM against a small synthetic peptide or a larger chimeric protein substrate, respectively. LY2811376 treatment yields a concentration-dependent decrease in A $\beta$  secretion in APP-overexpressing HEK293 cells.

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

LY2811376 inhibits A\beta secretion with EC50 of  ${\sim}100$  nM in primary neuronal cultures of PDAPP transgenic mouse. [1]

Administration of LY2811376 (10, 30, and 100 mg/kg doses) results in dose-dependent, significant reductions in A $\beta$ , as well as sAPP $\beta$  and C99, the proximal cleavage products of APP proteolysis by BACE1 in APP<sup>V717F</sup> mouse model of A $\beta$  pathology. After treatment with LY2811376 (5 mg/kg), reductions in A $\beta_{1-x}$  are observed in plasma, with a maximal 85% reduction observed from 4 to 12 h after dosing in beagle dogs.

Approximately 10-fold selectivity toward BACE1 over BACE2.

#### References

[1] May P, et al. J Neurosci, 2011, 31(46), 16507-16516.

[2] Yang HC, et al. J Neurochem, 2004, 91(6), 1249-1259.



Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.